Clinically Inactive Disease and Remission in Patients With Juvenile Idiopathic Arthritis Receiving Tofacitinib: Post Hoc Analysis of a Phase III Trial
In patients with JIA receiving tofacitinib, JADAS10-CID and ACR-CID rates improved rapidly and were sustained over time, and a small proportion of patients achieved JADAS10 remission. Inactive disease is a feasible treatment target in patients receiving tofacitinib. (ClinicalTrials.gov: NCT02592434).
Authors
- Lori Stockert
- Carlos Abud‐Mendoza (ORCID: https://orcid.org/0000-0002-3749-5831)
- Alessandro Consolaro (ORCID: https://orcid.org/0000-0002-0065-7614)
- Hermine I. Brunner (ORCID: https://orcid.org/0000-0001-9478-2987)
- Irina Lazariciu
- О.B. Synoverska (ORCID: https://orcid.org/0000-0003-1072-3782)
- Yulia Vyzhga (ORCID: https://orcid.org/0000-0002-3237-9962)
- Daniel J. Lovell (ORCID: https://orcid.org/0000-0003-1604-0130)
- Е.I. Alexeeva (ORCID: https://orcid.org/0000-0002-3874-4721)
- Mary Jane Cadatal
- Nicolino Ruperto (ORCID: https://orcid.org/0000-0001-8407-7782)
- Peter Chiraseveenuprapund (ORCID: https://orcid.org/0000-0002-6551-1384)
- Alberto Spindler
- Annette Diehl
- Jeffrey Chaitow
Institutions
- Cincinnati Children's Hospital Medical Center (US)
- Ivano-Frankivsk National Medical University (UA)
- Sechenov University (RU)
- Pfizer (United States) (US)
- Istituto Giannina Gaslini (IT)
- Children's Hospital at Westmead (AU)
- Rady Children's Hospital-San Diego (US)
- Hospital Central Dr. Ignacio Morones Prieto (MX)
- National Pirogov Memorial Medical University, Vinnytsya (UA)
- Hospital Privado (AR)
- University of Milano-Bicocca (IT)
Publication Details
- Journal
- The Journal of Rheumatology
- Published
- 2025-05-01
- DOI
- https://doi.org/10.3899/jrheum.2024-0536
- Citations
- 2
- Primary Topic
- Autoimmune and Inflammatory Disorders Research
- Type
- article
- Field-Weighted Citation Impact
- 3.54
Funders
- Pfizer